ORR and DCR were higher among LGG (29% and 71%, respectively) compared to patients with HGG (10% and 57%, respectively).9 Interestingly, in the RAGNAR study, a 26-year-old female with a FGFR1-K656E fusion-positive LGG, presented a complete tumor response lasting for at least 21.7 months9 (Table 1). Here, FGFR1 is linked to neoplasm.